Clene Inc. (CLNN)
4.84
-0.11 (-2.22%)
At close: Jan 14, 2025, 3:59 PM
4.80
-0.83%
After-hours Jan 14, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 4.5 |
| Market Cap | 38.62M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -5.29 |
| PE Ratio (ttm) | -0.91 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 5 |
| Volume | 29,599 |
| Avg. Volume (20D) | 82,704 |
| Open | 4.94 |
| Previous Close | 4.95 |
| Day's Range | 4.80 - 5.10 |
| 52-Week Range | 3.82 - 11.00 |
| Beta | undefined |
About CLNN
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; com...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 18, 2018
Employees 82
Stock Exchange NASDAQ
Ticker Symbol CLNN
Website https://clene.com
Analyst Forecast
According to 5 analyst ratings, the average rating for CLNN stock is "Buy." The 12-month stock price forecast is $31, which is an increase of 540.50% from the latest price.
Buy 80.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Clene Inc. is scheduled to release its earnings on Mar 12, 2025,
before market opens.
Analysts project revenue of $156.00K, reflecting a -8.24% YoY shrinking and earnings per share of -0.87, making a -27.50% decrease YoY.
Analysts project revenue of $156.00K, reflecting a -8.24% YoY shrinking and earnings per share of -0.87, making a -27.50% decrease YoY.
5 months ago ·
Source
-23.47%
Clene shares are trading lower after the company r...
Unlock content with
Pro Subscription
9 months ago ·
Source
-6.49%
Clene shares are trading higher after the company announced Phase 2 VISIONARY-MS long term extension study results at the 2024 American Academy of Neurology Annual Meeting.
